A phase-1 dose escalation study for PFK-158, a first-in-human, first-in-class, small molecule inhibitor of PFKFB3, showed commendable tolerance and tumor burden reduction in pancreatic cancer, renal cell carcinoma, and adenocystic carcinoma patients [101,102,103]. Here, PFKFB3 is linked to neoplasm.